Business, energy, technology, markets and global industry news from Business News Today

Rocket Pharmaceuticals

PharmaDeviceNews Rocket Pharmaceuticals
Editorial infographic illustrating Affinia Therapeutics’ AFTX-201 BAG3 heart gene therapy programme, featuring an anatomical heart, DNA strands and clinical research imagery, with highlights on the 22-patient trial, promising animal results and unproven human safety and efficacy.
Pharma & Biotech

Affinia presents AFTX-201 preclinical data and UPBEAT trial design at HFSA 2026

Affinia advances AFTX-201 into a 22-patient BAG3 heart gene therapy trial after promising animal results. Human safety and efficacy remain unproven.

Read More
Pharma & Biotech

Rocket Pharmaceuticals gets FDA path to complete RP-A501 Danon disease pivotal trial

FDA clears Rocket Pharmaceuticals to continue its recalibrated RP-A501 pivotal trial, restoring a defined accelerated approval path in Danon disease.

Read More